| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 12:46 | Immunai and Boehringer partner to identify T-cell targets | ||
| 12:46 | Tryngolza charts blockbuster course after FDA's hypertriglyceridemia approval | ||
| 11:46 | Lilly-backed Absci banks $100m to progress endometriosis, hair loss therapy | ||
| 11:46 | Ionis grants Recordati rights to zilganersen for Alexander disease | ||
| 08:46 | BIO 2026: Former FDA staff question agency's "radical transparency" approach | ||
| Do | Merck KGaA to buy Bio-Techne for $11.3bn in life science footprint expansion | ||
| Do | MSD's Keytruda-Padcev combo secures EC approval for MIBC | ||
| Do | RQ Bio secures $115m to develop influenza antibody programme | ||
| Do | BIO 2026: How NIH cuts have threatened US competitiveness against China | ||
| Mi | Novartis targets undruggable cancers with $1.9bn Antares Therapeutics deal | ||
| Mi | OURA and Lilly join forces to harmonise drug-wearable obesity care | ||
| Mi | Boehringer and Combotope partner for cancer antibodies | ||
| Mi | Haisco and Nuvectis sign licensing deal for two drugs | ||
| Di | BIO 2026: NVIDIA announces the BioNeMo toolkit for AI agents | ||
| Di | FDA changes rare disease tune again as it clears path for Regenxbio's gene therapy | ||
| Di | Genprex's Reqorsa combo secures Canadian patent for lung cancer | ||
| Di | BIO 2026: Drug manufacturers band together to tackle employment challenges | ||
| Di | Lilly and BioArctic sign deal to develop neurodegenerative therapy | ||
| Mo | AbbVie deepens immunology legacy in $10.9bn Apogee buyout | ||
| Mo | HLTH Europe 2026: enriching the patient journey with health technologies | ||
| Mo | Moderna's mRNA flu vaccine passes FDA AdCom, review underway | ||
| Mo | Moderna's mRNA flu vaccine set for FDA review after positive AdCom | ||
| Mo | Sun Pharma to acquire Innovcare Lifesciences for $28.7m | ||
| Mo | Japan approves Sanofi's Sarclisa combo for MM treatment | ||
| 19.06. | Biopharma industry confidence at highest in years despite geopolitical headwinds |